Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25097362 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2CA12CA2CA9GRIA4 | |
| SCHEMBL12855688 | 0.86 | ADH1B (0.44) | SMN1; SMN2CA12CA2CA9ALDH1A1 | |
| SCHEMBL13213122 | 0.86 | ADH1B (0.44) | SMN1; SMN2CA12CA2CA9ALDH1A1 | |
| SCHEMBL25587867 | 0.82 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL25587870 | 0.82 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL25587869 | 0.82 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL5497061 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2CA12CA2CA9GRIA4 | |
| SCHEMBL5254185 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2CA12CA2CA9ALDH1A1 | |
| SCHEMBL18643152 | 0.76 | — | — | |
| SCHEMBL23613034 | 0.76 | CA1 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | SMN1; SMN2 2329/4885CA12 3202/4885CA2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.